|
Divi's Laboratories Limited (Divislab.NS) Valoración de DCF
IN | Healthcare | Drug Manufacturers - Specialty & Generic | NSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Divi's Laboratories Limited (DIVISLAB.NS) Bundle
¡Mejore sus opciones de inversión con la calculadora DCF (Divislabns)! Explore los datos financieros genuinos para los Laboratorios Limitados de Divi, ajuste las proyecciones y gastos de crecimiento, y observe instantáneamente cómo estas alteraciones afectan el valor intrínseco de (DivisLabns).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52,911.7 | 68,583.4 | 87,992.3 | 77,675.1 | 78,450.0 | 87,705.3 | 98,052.5 | 109,620.4 | 122,553.1 | 137,011.6 |
| Revenue Growth, % | 0 | 29.62 | 28.3 | -11.73 | 0.99762 | 11.8 | 11.8 | 11.8 | 11.8 | 11.8 |
| EBITDA | 20,128.3 | 29,237.2 | 39,970.0 | 27,137.7 | 25,430.0 | 33,933.0 | 37,936.3 | 42,411.9 | 47,415.5 | 53,009.5 |
| EBITDA, % | 38.04 | 42.63 | 45.42 | 34.94 | 32.42 | 38.69 | 38.69 | 38.69 | 38.69 | 38.69 |
| Depreciation | 1,862.4 | 2,555.9 | 3,115.1 | 3,431.8 | 3,780.0 | 3,512.3 | 3,926.7 | 4,389.9 | 4,907.8 | 5,486.8 |
| Depreciation, % | 3.52 | 3.73 | 3.54 | 4.42 | 4.82 | 4 | 4 | 4 | 4 | 4 |
| EBIT | 18,265.9 | 26,681.3 | 36,854.9 | 23,705.9 | 21,650.0 | 30,420.7 | 34,009.6 | 38,022.0 | 42,507.7 | 47,522.6 |
| EBIT, % | 34.52 | 38.9 | 41.88 | 30.52 | 27.6 | 34.69 | 34.69 | 34.69 | 34.69 | 34.69 |
| Total Cash | 10,255.1 | 20,849.6 | 27,417.7 | 42,191.6 | 37,010.0 | 32,001.2 | 35,776.6 | 39,997.4 | 44,716.1 | 49,991.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 14,133.5 | 16,765.2 | 24,238.8 | 17,930.0 | 20,890.0 | 22,525.3 | 25,182.8 | 28,153.8 | 31,475.3 | 35,188.6 |
| Account Receivables, % | 26.71 | 24.44 | 27.55 | 23.08 | 26.63 | 25.68 | 25.68 | 25.68 | 25.68 | 25.68 |
| Inventories | 18,638.6 | 21,452.3 | 28,286.2 | 30,004.1 | 31,840.0 | 31,199.5 | 34,880.3 | 38,995.3 | 43,595.9 | 48,739.2 |
| Inventories, % | 35.23 | 31.28 | 32.15 | 38.63 | 40.59 | 35.57 | 35.57 | 35.57 | 35.57 | 35.57 |
| Accounts Payable | 5,907.2 | 7,632.0 | 7,957.0 | 7,620.0 | 6,410.0 | 8,650.6 | 9,671.1 | 10,812.1 | 12,087.7 | 13,513.7 |
| Accounts Payable, % | 11.16 | 11.13 | 9.04 | 9.81 | 8.17 | 9.86 | 9.86 | 9.86 | 9.86 | 9.86 |
| Capital Expenditure | -11,832.1 | -9,101.9 | -7,132.0 | -4,730.2 | -10,030.0 | -10,983.1 | -12,278.8 | -13,727.4 | -15,346.9 | -17,157.5 |
| Capital Expenditure, % | -22.36 | -13.27 | -8.11 | -6.09 | -12.79 | -12.52 | -12.52 | -12.52 | -12.52 | -12.52 |
| Tax Rate, % | 26.03 | 26.03 | 26.03 | 26.03 | 26.03 | 26.03 | 26.03 | 26.03 | 26.03 | 26.03 |
| EBITAT | 13,819.3 | 19,858.5 | 29,620.5 | 18,255.1 | 16,014.8 | 23,206.9 | 25,944.8 | 29,005.7 | 32,427.7 | 36,253.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -23,015.3 | 9,591.9 | 11,621.1 | 21,210.6 | 3,758.9 | 16,982.0 | 12,274.9 | 13,723.1 | 15,342.1 | 17,152.1 |
| WACC, % | 6.03 | 6.03 | 6.03 | 6.03 | 6.03 | 6.03 | 6.03 | 6.03 | 6.03 | 6.03 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 63,379.8 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 17,838 | |||||||||
| Terminal Value | 877,533 | |||||||||
| Present Terminal Value | 654,731 | |||||||||
| Enterprise Value | 718,111 | |||||||||
| Net Debt | -3,600 | |||||||||
| Equity Value | 721,711 | |||||||||
| Diluted Shares Outstanding, MM | 265 | |||||||||
| Equity Value Per Share | 2,718.60 |
What You Will Receive
- Authentic DIVISLABNS Financial Data: Comes populated with Divi's Laboratories’ historical and forecasted financials for accurate evaluation.
- Completely Customizable Template: Easily adjust essential parameters such as revenue growth, WACC, and EBITDA percentage.
- Instant Calculations: Watch the intrinsic value of Divi's Laboratories update in real-time as you make adjustments.
- Expert Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF outcomes.
- Intuitive Interface: A straightforward layout and clear guidelines suitable for users of all experience levels.
Key Features
- Comprehensive DCF Calculator: Offers extensive unlevered and levered DCF valuation frameworks.
- WACC Calculator: Ready-to-use Weighted Average Cost of Capital sheet with adjustable inputs.
- Customizable Forecast Assumptions: Adapt growth rates, capital expenditures, and discount rates to your needs.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Divi's Laboratories Limited (DIVISLABNS).
- Interactive Dashboard and Charts: Visual representations highlight essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Explore Divi's Laboratories Limited’s (DIVISLABNS) pre-filled financial data and projections.
- Step 3: Adjust essential inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose the DIVISLABNS Calculator?
- Precision: Utilizes authentic Divi's Laboratories Limited (DIVISLABNS) financials for reliable data.
- Adaptability: Allows users to easily test and alter inputs according to their needs.
- Efficiency: Eliminate the need to create a DCF model from the ground up.
- High-Quality: Crafted with the expertise and usability standards expected at the CFO level.
- Intuitive: Designed to be accessible for users with varying levels of financial modeling experience.
Who Can Benefit from This Product?
- Investors: Accurately evaluate the fair value of Divi's Laboratories Limited (DIVISLABNS) prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for comprehensive financial reporting and analysis.
- Consultants: Effortlessly customize the template for client valuation reports.
- Entrepreneurs: Gain valuable insights into the financial modeling practices employed by leading companies.
- Educators: Implement this resource as a teaching aid to illustrate various valuation methodologies.
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Divi's Laboratories Limited (DIVISLABNS), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for calculating the Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models that present intrinsic value along with detailed calculations.
- Financial Statements: Pre-loaded annual and quarterly financial statements to facilitate in-depth analysis.
- Key Ratios: Includes key metrics for profitability, leverage, and efficiency relevant to Divi's Laboratories Limited (DIVISLABNS).
- Dashboard and Charts: A visual summary of valuation outputs and assumptions, designed for easy analysis of results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.